Celyad Oncology S.A.
CYAD · NASDAQ
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.04 | 0.11 | 0.01 |
| FCF Yield | 0.00% | -25.13% | -60.76% | -89.20% |
| EV / EBITDA | 0.00 | -2.16 | -1.38 | -1.20 |
| Quality | ||||
| ROIC | 0.00% | -28.80% | -34.43% | -90.31% |
| Gross Margin | 98.26% | 35.71% | 56.90% | -902.27% |
| Cash Conversion Ratio | 0.93 | 1.46 | 2.23 | 0.44 |
| Growth | ||||
| Revenue 3-Year CAGR | 196.94% | -42.43% | -68.03% | -75.92% |
| Free Cash Flow Growth | 0.00% | 62.02% | 14.13% | 25.92% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 1.88 | 1.37 | 1.00 |
| Interest Coverage | -555.00 | 0.00 | -74.79 | -277.33 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.02 | 0.00 |
| Cash Conversion Cycle | 0.00 | -10,124.29 | 4,374.99 | 617.06 |